Evidence map›Paper›PMID 22193214›Full record

ReviewRheumatology international2012

A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.

Philip G Conaghan

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04885751 (Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy in Patients With NSAIDs and Low Dose Steroid), which is not on this map. Cited by 131 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 5 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04885751 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy in Patients With NSAIDs and Low Dose Steroid: A Single-center, Randomized, Open Labeled, Pilot Study

TypeinterventionalSponsorSeoul National University Boramae HospitalRan2021 to 2022Enrolled50ConditionsRheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, Other Musculoskeletal DisorderArmsEupatilin, Rebamipide
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 5 syntheses or guidelines pooled it, 412 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Celecoxib for rheumatoid arthritis.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Celecoxib for osteoarthritis.The Cochrane database of systematic reviews · 2017
    Pooled it
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Philip G ConaghanSection of Musculoskeletal Disease, Department of Musculoskeletal Medicine, Leeds Institute of Molecular Medicine, University of Leeds, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. p.conaghan@leeds.ac.uk
Chapel Allerton Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) represent a diverse class of drugs and are among the most commonly used analgesics for arthritic pain worldwide, though long-term use is associated with a spectrum of adverse effects. The introduction of cyclooxygenase-2-selective NSAIDs early in the last decade offered an alternative to traditional NSAIDs with similar efficacy and improved gastrointestinal tolerability; however, emerging concerns about cardiovascular safety resulted in the withdrawal of two agents (rofecoxib and valdecoxib) in the mid-2000s and, subsequently, in an overall reduction in NSAID use. It is now understood that all NSAIDs are associated with some varying degree of gastrointestinal and cardiovascular risk. Guidelines still recommend their use, but little is known of how patients use these agents. While strategies and guidelines aimed at reducing NSAID-associated complications exist, there is a need for evidence-based algorithms combining cardiovascular and gastrointestinal factors that can be used to aid treatment decisions at an individual patient level.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalCardiovascular DiseasesCyclooxygenase 2 InhibitorsEvidence-Based MedicineGastrointestinal HemorrhageGuideline AdherenceHumansNonprescription DrugsPainPatient SafetyPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentRisk FactorsSafety-Based Drug WithdrawalsAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsNonprescription Drugs

Identifiers

PMID22193214
PMCPMC3364420
OpenAlexW2068984440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.